Immunologic Effects of Hydroxyurea in Sickle Cell Anemia
Open Access
- 1 October 2014
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 134 (4) , 686-695
Abstract
BACKGROUND AND OBJECTIVE: Susceptibility to encapsulated bacteria is well known in sickle cell disease (SCD). Hydroxyurea use is common in adults and children with SCD, but little is known about hydroxyurea’s effects on immune function in SCD. Because hydroxyurea inhibits ribonucleotide reductase, causing cell cycle arrest at the G1–S interface, we postulated that hydroxyurea might delay transition from naive to memory T cells, with inhibition of immunologic maturation and vaccine responses. METHODS: T-cell subsets, naive and memory T cells, and antibody responses to pneumococcal and measles, mumps, and rubella vaccines were measured among participants in a multicenter, randomized, double-blind, placebo-controlled trial of hydroxyurea in infants and young children with SCD (BABY HUG). RESULTS: Compared with placebo, hydroxyurea treatment resulted in significantly lower total lymphocyte, CD4, and memory T-cell counts; however, these numbers were still within the range of historical healthy controls. Antibody responses to pneumococcal vaccination were not affected, but a delay in achieving protective measles antibody levels occurred in the hydroxyurea group. Antibody levels to measles, mumps, and rubella showed no differences between groups at exit, indicating that effective immunization can be achieved despite hydroxyurea use. CONCLUSIONS: Hydroxyurea does not appear to have significant deleterious effects on the immune function of infants and children with SCD. Additional assessments of lymphocyte parameters of hydroxyurea-treated children may be warranted. No changes in current immunization schedules are recommended; however, for endemic disease or epidemics, adherence to accelerated immunization schedules for the measles, mumps, and rubella vaccine should be reinforced.Keywords
This publication has 25 references indexed in Scilit:
- Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & ImmunologyJournal of Allergy and Clinical Immunology, 2012
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Multivariate analysis of the relation between immune dysfunction and treatment intensity in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2011
- Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic reviewLeukemia, 2006
- Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccinationThe Journal of Pediatrics, 2003
- Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” AgentMedicine, 1996
- Clinical and hematologic effects of hydroxyurea in children with sickle cell anemiaThe Journal of Pediatrics, 1996
- Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen yearsThe Pediatric Infectious Disease Journal, 1996
- Serum antibodies to pneumococcal C polysaccharide in childrenThe Pediatric Infectious Disease Journal, 1987
- BACTERIAL INFECTION AND SICKLE CELL ANEMIAMedicine, 1971